Growth and differentiation of bone marrow hematopoietic cells in mice bearing Ehrlich ascite tumor and treated with Dicyclopentadienildichiorotitanium (IV)

Página do item simplificado
dc.contributor.authorValadares, M. C.
dc.contributor.authorKlein, S. I.
dc.contributor.authorZyngier, S.
dc.contributor.authorQueiroz, MLS
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2014-05-20T15:24:24Z
dc.date.available2014-05-20T15:24:24Z
dc.date.issued1998-10-01
dc.description.abstractIn this work we have:investigated the growth and differentiation of bone marrow stem cells in mice bearing Ehrlich ascites tumor-and treated with three dose-regimens of Dicyclopentadienyldichlorotitanium (IV) (DDCT). We also: studied the presence of colony stimulating factors In the serum of PDCT-treated animals as well-as the effects-of the drug on the survival of the tumor-bearing mice. The-results demonstrated that the myelosuppression developed in the tumor-bearing animals is prevented by the administration:of 1, 2 or 3 doses of 15 mg/kg DDCT. In the treatment with three doses, however, 23 % of the animals died. Moreover, DDCT treatment in normal animals resulted in increased numbers of CFU-GM. We observed the presence of stimulating factors in the serum of drug-treated animals which induced the growth and differentiation of bone marrow progenitor cells from normal animals in vitro. on the other hand, in vitro addition of the drug to these cultures had no effect. Thus, we conclude that the drug protects against the myelosuppression induced by the tumor and that this protection may be related to an indirect action of the drug. (C) 1998 International Society for Immunopharmacology. Published by Elsevier B.V. Ltd.en
dc.description.affiliationState Univ Campinas, Fac Med Sci, Dept Pharmacol, BR-13083970 Campinas, SP, Brazil
dc.description.affiliationState Univ São Paulo, UNESP, Chem Inst Araraquara, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Pharmacol, São Paulo, Brazil
dc.description.affiliationUnespState Univ São Paulo, UNESP, Chem Inst Araraquara, São Paulo, Brazil
dc.format.extent573-581
dc.identifierhttp://dx.doi.org/10.1016/S0192-0561(98)00058-7
dc.identifier.citationInternational Journal of Immunopharmacology. Oxford: Pergamon-Elsevier B.V., v. 20, n. 10, p. 573-581, 1998.
dc.identifier.doi10.1016/S0192-0561(98)00058-7
dc.identifier.issn0192-0561
dc.identifier.urihttp://hdl.handle.net/11449/35017
dc.identifier.wosWOS:000077009300005
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Immunopharmacology
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectEhrlich ascites tumorpt
dc.subjecthematopoietic cellspt
dc.subjectmyeloprotectionpt
dc.subjecttitanocenept
dc.subjectantitumorpt
dc.titleGrowth and differentiation of bone marrow hematopoietic cells in mice bearing Ehrlich ascite tumor and treated with Dicyclopentadienildichiorotitanium (IV)en
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos